STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLDX
  4. [Form 4] Celldex Therapeutics, Inc. Insider Trading Activity

Celldex (NASDAQ: CLDX) grants 100,000 options to senior VP & CPDO

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. reported that senior vice president and chief product development officer Elizabeth Crowley received a grant of options covering 100,000 shares of common stock. These incentive stock options have an exercise price of $34.09 per share and expire on June 25, 2036.

According to the disclosure, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters. After this grant, Crowley holds derivative securities representing 100,000 options directly.

Positive

  • None.

Negative

  • None.

Insights

Routine equity grant of 100,000 options to a senior executive.

Celldex granted senior executive Elizabeth Crowley incentive stock options over 100,000 shares at an exercise price of $34.09, expiring on June 25, 2036. The grant is made under the company’s 2021 Omnibus Equity Incentive Plan.

The vesting structure is typical for long-term incentives: 25% vests on June 25, 2027, with the remainder vesting quarterly over the subsequent 12 quarters. This aligns Crowley’s potential upside with future share-price performance over many years.

As a compensation-related, non-cash transaction classified as a grant/award acquisition, it does not represent an open-market purchase or sale. From an investment thesis perspective, this appears to be a standard executive equity award rather than a directional signal.

Insider Crowley Elizabeth
Role SR. VP & CPDO
Type Security Shares Price Value
Grant/Award Incentive Stock Option (right to buy) 100,000 $0.00 --
Holdings After Transaction: Incentive Stock Option (right to buy) — 100,000 shares (Direct, null)
Footnotes (1)
  1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Options granted 100,000 options Incentive Stock Option grant to Elizabeth Crowley
Exercise price $34.09 per share Strike price of Incentive Stock Options
Initial vesting date June 25, 2027 25% of options vest on this date
Vesting schedule remainder 12 quarterly installments Remaining 75% vest over subsequent 12 quarters
Expiration date June 25, 2036 Option term end date
Incentive Stock Option financial
"Incentive Stock Option (right to buy)"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
2021 Omnibus Equity Incentive Plan financial
"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."
grant/award acquisition financial
"transaction_action: grant/award acquisition"
vesting financial
"25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Crowley Elizabeth
(Last)(First)(Middle)
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
(Street)
HAMPTON NEW JERSEY 08827
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SR. VP & CPDO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Incentive Stock Option (right to buy)(1)$34.0906/25/2026(1)A100,00006/25/2027(2)06/25/2036Common Stock100,000$0100,000D
Explanation of Responses:
1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Sam Martin, attorney-in-fact for Elizabeth Crowley06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Celldex Therapeutics (CLDX) report in this Form 4 for Elizabeth Crowley?

Celldex reported that Senior VP & CPDO Elizabeth Crowley received a grant of incentive stock options for 100,000 shares. The options are a compensation award, not an open-market trade, and give her the right to buy Celldex common stock at a fixed exercise price.

How many Celldex (CLDX) shares are covered by Elizabeth Crowley’s new stock options?

The grant covers options on 100,000 shares of Celldex common stock. These derivative securities allow Crowley to purchase shares at a preset exercise price if they vest and are exercised, creating potential equity exposure tied to future company performance.

What is the exercise price of Elizabeth Crowley’s Celldex (CLDX) stock options?

The options have an exercise price of $34.09 per share. This means Crowley can buy Celldex common stock at $34.09 if she exercises vested options before expiration, so the economic value depends on future market prices relative to this strike level.

When do Elizabeth Crowley’s Celldex (CLDX) stock options vest?

Twenty-five percent of the options vest on June 25, 2027. The remaining 75% then vest in equal quarterly installments over the following 12 quarters, creating a multi-year vesting schedule that encourages ongoing service and long-term alignment with shareholders.

When do Elizabeth Crowley’s Celldex (CLDX) stock options expire?

The options expire on June 25, 2036, if not exercised earlier. After that date, any unexercised options become worthless. This long-dated term gives Crowley an extended window to benefit if Celldex’s share price rises above the exercise price.

Is this Celldex (CLDX) Form 4 transaction a buy or sell of shares?

The transaction is an acquisition of derivative securities through a grant, not a market buy or sell. Crowley received incentive stock options as compensation, classified as a grant/award acquisition, and no open-market purchase or sale of common shares is reported here.